UK markets open in 52 minutes

NIKKEI 225
38,254.98
-19.07(-0.05%)
HANG SENG
18,214.40
+451.37(+2.54%)
CRUDE OIL
79.50
+0.50(+0.63%)
GOLD FUTURES
2,324.90
+13.90(+0.60%)
DOW
37,903.29
+87.37(+0.23%)
Bitcoin GBP
45,891.71
-1,853.48(-3.88%)

Family finances

Who is the breadwinner in your family and does it matter?

REGN Jan 2025 600.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

176.87

0.00

(0.00%)

As of 10:05AM EDT. Market open.

Zacks
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Zacks
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
Zacks
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.